Cedric Darcis

Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The private company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

dcinex SA provides digital cinema services. It offers solutions to digital cinema services, from financial offering to deployment, along with maintenance, training, content and network services and alternative content. The company was founded in 2004 and is headquartered in Liege, Belgium.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France.

Miracor Medical SA engages in the development and manufacture of medical devices. Its product PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System has a driving console and associated catheters to improve outcomes for severe heart attack patients. It seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack. The company was founded by Werner Mohl in May, 2008 and is headquartered in Vienna, Austria.

Trasis SA develops solutions for the radiopharmaceutical and diagnostic imaging industries. The firm designs, manufactures and sells synthesizers, dispensers and their accessories, as well as shielding solutions to the needs of the radiochemistry industry. It offers pharmacy and hospital dispensers, dose administration products, and miniaturized medical instruments. The company was founded in 2004 and is headquartered in Ans, Belgium.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

UCB Pharma SA discovers and develops biopharmaceutical products. It is a biopharmaceutical company focuses on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The company is headquartered in Brussels, Belgium.

Part of Laboratoires S.M.B. SA, SMB Technology is a Belgian company that provides IT consulting services. The private company is based in Brussels, Belgium. The CEO of the company is Caroline Baudier.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Uteron Pharma SA is engaged in the research and development of controlled release devices. The firms products Levosert and Diafert provide pharmaceutical solutions for women's health. The company was founded by Stijn van Rompay in 2010 and is headquartered in Grâce-Hollogne, Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Part of InQpharm Group, Neem Biotech Ltd. is a British biotech company focused on developing groundbreaking ways of defeating big health challenges. The private company is based in St. Mellons, UK. Leveraging their unique position in antimicrobial R&D, they have expertise in drug discovery. Neem Biotech was acquired by InQpharm Group on August 09, 2012.

Novalon SA manufactures pharmaceutical products. It focuses on the development of therapeutically equivalent generic products that are complex to develop and manufacture. The firm develops the projects Zoreline and Myring, which are therapeutic equivalents to branded products. The company is headquartered in Liege, Belgium.

Part of AbbVie, Inc., Odyssea Pharma SPRL is a pharmaceutical development and Belgian production company. The private company is based in Grâce-Hollogne, Belgium.

A7 Software SA develops software for health sector. The firm is created to improve communication between doctor and patients. The company was founded by Vincent Keunen and Maite Grisard on November 12, 2014 and is headquartered in Boncelles, Belgium.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

Zaluvida Holdings Pte Ltd. provides solutions that improve the lives of livestock and protect the planet. Zaluvida Holdings is based in Singapore, Singapore. The Singaporean company also offers products that help pets stay healthier. The private company's focus is on developing new alternatives to antibiotics that can benefit farmers. and has subsidiaries in Switzerland, Germany, and Malaysia.

Belma Technologies SA is a Belgian company that specializes in biotechnological research and development. The company is based in Liege, Belgium. Belma Technologies was founded in 2015 by Brigitte Evrard, Maria Alvarez Gonzalez.

Hedera 22 SCRL supplies and leases computers and office equipment. The company was founded by Sébastien Rigali, Pierre Tocquin, Marc Hanikenne and Denis Baurain on May 25, 2015 and is headquartered in Esneux, Belgium.

AuXin Surgery SA develops, manufactures, and supplies combined medical devices for non-invasive surgery. The private company is based in Ottignies-Louvain-la-Neuve, Belgium. The Belgian company was founded in 2014 by Philippe Capart, Cecile Capart, Herve Capart, Carlo Zini, and Gilles Capart. The CEO is Benoît Verjans.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

Upper Room SAS provides film and television production services. The private company is based in Paris, France.

EXO Biologics SA operates as a Belgian biotechnology company. The company is based in Liege, Belgium. The company was founded in 2019. Hugues Wallemacq has been the CEO of the company since 2021.

Odix SA is a Belgian cybersecurity company that specializes in developing and marketing advanced anti-malware tools for enterprises of all sizes. The company is based in Thimister-Clermont, Belgium and was founded in 2020. The company's patented content disarm and reconstruction (TrueCDR™) technology is trusted by companies in various sectors, including industrial, finance, insurance, and government. The CEO is Valérie Gordenne.

Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018.